Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samish Dhungana

Neurology Maruetta, GA Medical Doctor

NPI 1316275035 CMS profile 1361551

677 Church Street, Neurology Department, Maruetta, GA 30060

Open in the dashboard

General payments

$8,896

487 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samish Dhungana of Maruetta, GA is reported in the CMS Open Payments database as having received $8,896 across 487 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,668 73
2024 General $1,368 60
2023 General $1,381 71
2022 General $1,024 62
2021 General $1,084 80
2020 General $617 40
2019 General $1,754 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samish Dhungana
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Samish Dhungana were reported at $1,668. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Samish Dhungana Neurology median Middle half National median
2019 $1,754 $474 $118–$2,177 $163
2020 $617 $367 $82–$2,309 $114
2021 $1,084 $438 $104–$2,547 $132
2022 $1,024 $442 $103–$2,388 $149
2023 $1,381 $464 $119–$2,312 $160
2024 $1,368 $468 $119–$2,323 $164
2025 $1,668 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,929 148 payments
  2. EMD Serono, Inc. $584 26 payments
  3. UCB, Inc. $473 14 payments
  4. Celgene Corporation $364 13 payments
  5. Alexion Pharmaceuticals, Inc. $327 15 payments
  6. Allergan Inc. $326 21 payments
  7. ACADIA Pharmaceuticals Inc $322 16 payments
  8. Amgen Inc. $319 19 payments
  9. Eisai Inc. $282 13 payments
  10. Novartis Pharmaceuticals Corporation $243 15 payments
  11. Other $3,727 187 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,547 480 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $299 6 payments
  3. Education $50 1 payment
Products named General payments · program years 2019–2025
  1. QULIPTA $832 72 payments
  2. UBRELVY $718 60 payments
  3. ZEPOSIA $407 15 payments
  4. AIMOVIG $357 22 payments
  5. BOTOX Hyperhydrosis $352 23 payments
  6. BOTOX Botox Therapeutic $332 14 payments
  7. NURTEC ODT $200 8 payments
  8. Zilbrysq $200 1 payment
  9. VALTOCO $200 9 payments
  10. NUPLAZID $196 9 payments
  11. Other $5,723 301 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

4,914

Median for Neurology: 833

Drug cost

$365,138

Median for Neurology: $202,670

Branded share of claims

20.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Qulipta Atogepant Brand 84 $89,979
Aimovig Autoinjector Erenumab-Aooe Brand 74 $61,913
Ubrelvy Ubrogepant Brand 43 $46,007
Nurtec Odt Rimegepant Sulfate Brand 13 $23,722
Ajovy Autoinjector Fremanezumab-Vfrm Brand 16 $11,525
Sumatriptan Succinate Generic 105 $10,604
Galantamine Hbr Generic 106 $10,288
Memantine Hcl Generic 288 $8,399
Gabapentin Generic 444 $6,919
Sumatriptan Generic 12 $6,840

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$128,632

Of which drugs: $35,668

Medicare patients

667

Average age 75

Services billed

9,118

385 women, 282 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 39%
Diabetes 33%
Depression 32%
Chronic kidney disease 30%
Atrial fibrillation 25%
Alzheimer's or dementia 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 16 8,000 $35,664

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPOSIA
  • Celgene Corporation $185
$185 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $111
$111 — —
QULIPTA
  • AbbVie, Inc. $105
$105 84 —
UBRELVY
  • AbbVie, Inc. $100
$100 43 —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

487 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record